TD Cowen raised the firm’s price target on GSK (GSK) to $70 from $55 and keeps a Hold rating on the shares. The firm said the company’s new CEO appears poised to bolster an already solidly-performing business and R&D operation. Key launches and pipeline catalysts over next 12 months should build confidence in GBP 40B sales target by 2031, which is well above expectations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- Balancing Blenrep Upside With Valuation and Execution Risks: Why the Risk‑Reward Remains a Hold
- Balancing Strategic Promise and Execution Risk: Justifying a Hold Rating on GSK
- GSK Earnings Call: Specialty Strength Amid Vaccine Drags
- Trump Trade: Argentina says U.S. to cut hundreds of tariffs
- GSK announces European Commission approved Nucala